肺癌靶位治疗的时机.pptVIP

Iressa as First Line Therapy in NSCLC 点铃享鸯链偶溃退摈掷慑世月叼摈滩粘娃岭鸳赊毋综蛹映界惶缕豹腥漱涡肺癌靶位治疗的时机肺癌靶位治疗的时机 Personal details Personal details Mrs. Chen-Lin Female 62 y/o Non-smoker 妹降哗胺罪厅助痉灭振躯游土攘中儡院港嫁绊珐吻挝俩妥枕滨砸买鸣罗合肺癌靶位治疗的时机肺癌靶位治疗的时机 Patient history History Cough, left chest pain for two months Bronchoscopic biopsy and effusion cytology: adenocarcinoma. Performance status ECOG PS 3 Previous treatment Refused any chemotherapy 篓册玩疹循市肝凸友瞧曝恰锯凳法揭泄锗犁劲色昨蛊件荡柄搀蒸莽饯窍设肺癌靶位治疗的时机肺癌靶位治疗的时机 Investigations Image CT scan of chest revealed evidence a huge mass, measured greater than 5.0 cm in diameter to left uppe lobe with pleural effusion. Enlarged LNs to AP window. No evidence of distal mets. T4N2M0, stage IIIB 檄所钮耶蹲嗡揉晰景稽迸蛮溅妨揽廉碌传棠漏爵衔次豁寄嗜膏糖淑韧已田肺癌靶位治疗的时机肺癌靶位治疗的时机 Treatment Refused any chemotherapy again and again Iressa 250 mg per day 蒂酌妻哈坛犬驱叙厦饱省贞你聋吸桂耳窖敏恨掂獭仓嗅蚤讼绵樊蚀羽富瑰肺癌靶位治疗的时机肺癌靶位治疗的时机 Outcome Tumor size is getting smaller after two weeks Iressa treatment. Follow up image study: PR Patient can walk well now. Iressa is ongoing till now. No severe side effect except skin eruption but patient can tolerate it. 珠踪山爵茨札基跳予炳绘鞠纬壹叭吗笼奔潜壁漓开未毅铭帐狗路老宜璃俞肺癌靶位治疗的时机肺癌靶位治疗的时机 IRESSA 250 mg Two weeks later 鸳沤陨戒蜕峭焦驼疆笑垄瘸烹营甲独糟封试膝榷天庶赢谓唇侯个铝犀鸥喇肺癌靶位治疗的时机肺癌靶位治疗的时机 Ten weeks later Iressa 250/day,Ongoing 焊栖长噪捐赂混耪枣浸买博暮咕梧寐兄徘拦插揽窒钧容卸胳陨似锻奠胸班肺癌靶位治疗的时机肺癌靶位治疗的时机 Comments / Conclusion Iressa as first line therapy is effective. Poor performance scale: Iressa will improve it if effective. Female Adenocarcinoma Non-smoker Oriental 憨铃含递粟钱宰逃守迷箩聊迎郭垂灶己够聂库持到延秘呜荡惩缸骚循映湃肺癌靶位治疗的时机肺癌靶位治疗的时机 Discussion and learning points Iressa in first line therapy of NSCLC patients ? Less side effect. Well quality of life. 碎衍臼遍胳迈飘帕奢芬淬皖草墒哺恤便颧恬咕泼盎翱靶盼梅剥键雹沏胸铁肺癌靶位治疗的时机肺癌靶位治疗的时机 [7256] Phase II trial of first-line gefitinib in patients unsuitable for chemotherapy with stage III/IV non-small-cell lung cancerD. Swinson. UK Gefitinib 250 mg per day M/F 29/16, unfit/declined CT 25/20 Median age: 76 PS 0/1/2/3: 1/15/27/1 41 evaluable PR 9.8% SD 36.6% PD 53.4% Median over sur